← Search & browse all drugs

necitumumab

L01FE03

Forms & Strengths

800 mg/50 mL solution for intravenous infusion
Intravenous formulation

Adult Dosing

840 mg administered as an intravenous infusion over 60 minutes on days 1 and 8 of a 21-day cycle
Dose reduction to 650 mg or 500 mg for adverse reactions

Pediatric Dosing

Safety and efficacy not established in pediatric patients
No dosing recommendations available for patients under 18 years

Indications

First-line treatment of patients with squamous non-small cell lung cancer (NSCLC)
Used in combination with gemcitabine and cisplatin

Mechanism of Action

Human IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR)
Blocks the ligand-binding site of EGFR, preventing receptor activation and downstream signaling

Contraindications

Hypersensitivity to necitumumab or any of its components
No contraindications in the presence of EGFR mutations

Adverse Reactions

Dermatologic toxicities, including rash and acne-like rash
Hypomagnesemia, hypocalcemia, and venous thromboembolic events
Increased risk of cardiac arrest and other cardiac complications

Drug Interactions

Increased risk of bleeding when used with anticoagulants or antiplatelet agents
Monitor for electrolyte imbalances when used with other medications that alter electrolyte levels

Curated Content: Needs Vetting Before Put to Clinical Use